Cimeio is a therapeutics company developing Shielded-Cell & Immunotherapy Pairs™ (SCIP), novel immunotherapies which have the potential to transform treatment of hematologic diseases. Cimeio develops state-of-the-art immunotherapies, along with paired, modified variants of naturally occurring cell surface proteins in HSCs. These novel epitope edited variants maintain their function but are resistant to depletion when targeted by the paired immunotherapy which has high affinity for the wild-type version of these proteins.

These immunotherapies have significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with hematologic malignancies, autoimmune disorders, and genetic diseases. Shielded Cell and Immunotherapy Pairs and SCIP are trademarks of Cimeio Therapeutics, Inc.

Using our cell-shielding technology and paired immunotherapies, we aim to develop curative therapies for patients with hematologic disorders.

Our proprietary immunotherapies deplete diseased cells, while our cell-shielding technology protects healthy cells.

Because the healthy cells are protected, the immunotherapy can be safely administered to boost engraftment or treat minimal residual disease.

We use gene editing tools to insert novel protein variants into HSCs or other types of cells, allowing the cells to maintain their function while making them resistant to depletion by the paired immunotherapy.

Our shielding technology has proven to be effective in shielding cells from depletion mediated by antibodies, T-cell engagers, ADCs, and CAR-T cells.